Jack’s Angels remains committed to the DIPG Research Fund (est. 2013) at Children’s Hospital Los Angeles through local fundraising efforts, our local children’s research institution, and is working actively in 2019 in research advocacy at the state and federal level. Research partner Children’s Cancer Therapy Development Institute is featured monthly on Childhood Cancer Talk Radio, where a project manager is interviewed and the parent-led foundation funding the research is featured. Jack’s Angels advocacy is geared toward raising awareness for DIPG, pediatric brain cancer, the leading cause of death in children with cancer, and the most successful research funding organizations for DIPG such as The Cure Starts Now and the DIPG Collaborative.
Equally important is the work of the Michael Mosier Defeat DIPG Foundation in Bethesda, MD, and the ChadTough Foundation in Ann Arbor, MI:Here in California, UCSF, Stanford University, and the Pacific Pediatric Neuro-Oncology Consortium are consistently making solid contributions to DIPG research and expanding in global collaboration.
Dr. Michelle Monje and her lab at Stanford University, with the Lucile Packard Children’s Hospital, is unparalleled in it’s commitment, among singular laboratories, to DIPG research. For more information, visit:http://neurology.stanford.edu/labs/monjelab/
Dr. Adam Green at the University of Colorado, Denver, directs an extensive laboratory devoted to DIPG research, and practices at Children’s Hospital Colorado. He has been a conferring expert along with Dr. Monje for the national DIPG Awareness Resolution in US Congress.
RESEARCH LISTINGS and Helpful Organizations:
Children’s Cancer Therapy Development Institute (CC-TDI): http://cc-tdi.org, a non-profit biotech company dedicated to bringing therapies to children with cancer from the most promising research. CC-TDI is a collaboration between families, scientists, advocates, and children’s cancer organizations, located in Portland, OR, Scientific Director Dr. Charles Keller
PNOC: Pacific Pediatric Neuro-Oncology Consortium
The Pacific Pediatric Neuro-Oncology Consortium (PNOC) is a network of 18 children’s hospitals that conduct clinical trials of new therapies for children with brain tumors. Our goal is to improve outcomes by translating the latest findings in cancer biology into better treatments for these children.
- CBTTC: Children’s Brain Tumor Tissue ConsortiumOpen-source data sharing, pooling of biospecimens, and real-time global research collaboration capabilities to fast track and boost bench-to-bedside innovations in the field of pediatric brain cancer.
- Leading pediatric brain cancer clinicians, researchers and institutions partnered for cutting edge scientific innovation and collaboration.
- The CBTTC is dedicated to find new innovative treatments for all types of pediatric brain tumors. Find out how you can be part of this ground-breaking initiative.
Visit also: http://www.justonemoreday.org, http://www.dipg.net , or http://www.thecurestartsnow.org for the latest in DIPG research. http://www.reflectionsofgrace.org remains a steadfast support of families facing a DIPG diagnosis.
We are on the threshold of discovery as more awareness is raised for the urgent need for research for the invariably terminal DIPG.
Hope is on the horizon with the DIPG registry at Children’s Hospital Cincinnati, involving an international collaboration of specialists from the US, Europe, and Australia in the standardization of data and collection of tumor samples from patients with DIPG. The Registry is supported by the DIPG Collaborative and a group of foundations specific to supporting DIPG research and those families afflicted with DIPG.“The registry is a database collecting basic information about DIPG patients as well as their medical history, imaging (scans), and any available biopsy results to link to a another database of results from testing available tumor samples. The registry is run by an international network of experts studying and treating DIPG. The data collected form a research continuum from basic biology to clinical practice to address our primary goals of 1, to have a better understanding of the biology of DIPG; 2, developing more effective therapies, and 3, developing new approaches to diagnosis, response assessment and multidisciplinary treatment and follow-up that will improve patient outcomes.”–www.dipgregistry.org
The Pediatric Brain Tumor Foundation (pbtf.us) is one of the leading sources of research funding for the latest in DIPG and pediatric brain tumor research. Their Research Advisory Board is unparalleled in its assessment and also the encouragement of graduate student work in the field.
We emphatically believe that progress in DIPG research will bring insight for all of neuro-oncology and will represent significant advances for medicine and our understanding of biology.
Jack’s Angels Foundation is dedicated to promoting awareness, support, and research for Diffuse Intrinsic Pontine Glioma, or DIPG. We are committed to promoting the most innovative research and clinical trials that will help shed light on the nature of DIPG and the genetic anomalies that cause it, that there be greater hope for survival. We appreciate very much your attention to the roughly 400 children afflicted by this uncompromising disease each year in the United States alone. The median survival time is 9 months.